Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Artiva Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022
Revenue	33.49	4.93
Revenue Growth (YoY)	579.21%	-
Gross Profit	33.49	4.93
Selling, General & Admin	13.91	20.78
Research & Development	50.25	43.98
Operating Expenses	64.16	64.76
Operating Income	-30.67	-59.83
Interest Expense / Income	-2.54	-1.29
Other Expense / Income	0.51	0.2
Pretax Income	-28.65	-58.74
Income Tax	0.07	0.05
Net Income	-28.72	-58.79
Free Cash Flow	-50.69	-57.13
Gross Margin	100.00%	100.00%
Operating Margin	-91.58%	-1213.32%
Profit Margin	-85.75%	-1192.21%
Free Cash Flow Margin	-151.34%	-1158.55%
EBITDA	-28.92	-58.87
EBITDA Margin	-86.34%	-1193.90%
Depreciation & Amortization	2.27	1.16
EBIT	-31.18	-60.03
EBIT Margin	-93.11%	-1217.38%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).